Adjuvant Chemoradiotherapy After Pancreatic Resection for Invasive Carcinoma Associated With Intraductal Papillary Mucinous Neoplasm of the Pancreas

Michael J. Swartz, Charles C. Hsu, Timothy M. Pawlik, Jordan Winter, Ralph H Hruban, Mehmet Guler, Richard D. Schulick, John L Cameron, Daniel Laheru, Christopher Wolfgang, Joseph M. Herman

Research output: Contribution to journalArticle

Abstract

Purpose: Intraductal papillary mucinous neoplasms are mucin-producing cystic neoplasms of the pancreas. One-third are associated with invasive carcinoma. We examined the benefit of adjuvant chemoradiotherapy (CRT) for this cohort. Methods and Materials: Patients who had undergone pancreatic resection at Johns Hopkins Hospital between 1999 and 2004 were reviewed. Of these patients, 83 with a resected pancreatic mass were found to have an intraductal papillary mucinous neoplasm with invasive carcinoma, 70 of whom met inclusion criteria for the present analysis. Results: The median age at surgery was 68 years. The median tumor size was 3.3 cm, and invasive carcinoma was present at the margin in 16% of the patients. Of the 70 patients, 50% had metastases to the lymph nodes and 64% had Stage II disease. The median survival was 28.0 months, and 2- and 5-year survival rate was 57% and 45%, respectively. Of the 70 patients, 40 had undergone adjuvant CRT. Those receiving CRT were more likely to have lymph node metastases, perineural invasion, and Stage II-III disease. The 2-year survival rate after surgery with vs. without CRT was 55.8% vs. 59.3%, respectively (p = NS). Patients with lymph node metastases or positive surgical margins benefited significantly from CRT (p = .047 and p = .042, respectively). On multivariate analysis, adjuvant CRT was associated with improved survival, with a relative risk of 0.43 (95% confidence interval, 0.19-0.95; p = .044) after adjusting for major confounders. Conclusion: Adjuvant CRT conferred a 57% decrease in the relative risk of mortality after pancreaticoduodenectomy for intraductal papillary mucinous neoplasms with an associated invasive component after adjusting for major confounders. Patients with lymph node metastases or positive margins appeared to particularly benefit from CRT after definitive surgery.

Original languageEnglish (US)
Pages (from-to)839-844
Number of pages6
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume76
Issue number3
DOIs
StatePublished - Mar 1 2010

Fingerprint

Adjuvant Chemoradiotherapy
pancreas
neoplasms
Pancreatic Neoplasms
cancer
Carcinoma
lymphatic system
Chemoradiotherapy
metastasis
Lymph Nodes
surgery
Neoplasm Metastasis
margins
Neoplasms
Survival Rate
adjusting
Pancreaticoduodenectomy
Survival
mortality
Mucins

Keywords

  • adjuvant therapy
  • intraductal papillary mucinous neoplasm
  • invasive carcinoma
  • Pancreatic adenocarcinoma
  • radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Adjuvant Chemoradiotherapy After Pancreatic Resection for Invasive Carcinoma Associated With Intraductal Papillary Mucinous Neoplasm of the Pancreas. / Swartz, Michael J.; Hsu, Charles C.; Pawlik, Timothy M.; Winter, Jordan; Hruban, Ralph H; Guler, Mehmet; Schulick, Richard D.; Cameron, John L; Laheru, Daniel; Wolfgang, Christopher; Herman, Joseph M.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 76, No. 3, 01.03.2010, p. 839-844.

Research output: Contribution to journalArticle

@article{fa2e36950abe4545924609dd2fc8e619,
title = "Adjuvant Chemoradiotherapy After Pancreatic Resection for Invasive Carcinoma Associated With Intraductal Papillary Mucinous Neoplasm of the Pancreas",
abstract = "Purpose: Intraductal papillary mucinous neoplasms are mucin-producing cystic neoplasms of the pancreas. One-third are associated with invasive carcinoma. We examined the benefit of adjuvant chemoradiotherapy (CRT) for this cohort. Methods and Materials: Patients who had undergone pancreatic resection at Johns Hopkins Hospital between 1999 and 2004 were reviewed. Of these patients, 83 with a resected pancreatic mass were found to have an intraductal papillary mucinous neoplasm with invasive carcinoma, 70 of whom met inclusion criteria for the present analysis. Results: The median age at surgery was 68 years. The median tumor size was 3.3 cm, and invasive carcinoma was present at the margin in 16{\%} of the patients. Of the 70 patients, 50{\%} had metastases to the lymph nodes and 64{\%} had Stage II disease. The median survival was 28.0 months, and 2- and 5-year survival rate was 57{\%} and 45{\%}, respectively. Of the 70 patients, 40 had undergone adjuvant CRT. Those receiving CRT were more likely to have lymph node metastases, perineural invasion, and Stage II-III disease. The 2-year survival rate after surgery with vs. without CRT was 55.8{\%} vs. 59.3{\%}, respectively (p = NS). Patients with lymph node metastases or positive surgical margins benefited significantly from CRT (p = .047 and p = .042, respectively). On multivariate analysis, adjuvant CRT was associated with improved survival, with a relative risk of 0.43 (95{\%} confidence interval, 0.19-0.95; p = .044) after adjusting for major confounders. Conclusion: Adjuvant CRT conferred a 57{\%} decrease in the relative risk of mortality after pancreaticoduodenectomy for intraductal papillary mucinous neoplasms with an associated invasive component after adjusting for major confounders. Patients with lymph node metastases or positive margins appeared to particularly benefit from CRT after definitive surgery.",
keywords = "adjuvant therapy, intraductal papillary mucinous neoplasm, invasive carcinoma, Pancreatic adenocarcinoma, radiotherapy",
author = "Swartz, {Michael J.} and Hsu, {Charles C.} and Pawlik, {Timothy M.} and Jordan Winter and Hruban, {Ralph H} and Mehmet Guler and Schulick, {Richard D.} and Cameron, {John L} and Daniel Laheru and Christopher Wolfgang and Herman, {Joseph M.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/j.ijrobp.2009.02.071",
language = "English (US)",
volume = "76",
pages = "839--844",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Adjuvant Chemoradiotherapy After Pancreatic Resection for Invasive Carcinoma Associated With Intraductal Papillary Mucinous Neoplasm of the Pancreas

AU - Swartz, Michael J.

AU - Hsu, Charles C.

AU - Pawlik, Timothy M.

AU - Winter, Jordan

AU - Hruban, Ralph H

AU - Guler, Mehmet

AU - Schulick, Richard D.

AU - Cameron, John L

AU - Laheru, Daniel

AU - Wolfgang, Christopher

AU - Herman, Joseph M.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Purpose: Intraductal papillary mucinous neoplasms are mucin-producing cystic neoplasms of the pancreas. One-third are associated with invasive carcinoma. We examined the benefit of adjuvant chemoradiotherapy (CRT) for this cohort. Methods and Materials: Patients who had undergone pancreatic resection at Johns Hopkins Hospital between 1999 and 2004 were reviewed. Of these patients, 83 with a resected pancreatic mass were found to have an intraductal papillary mucinous neoplasm with invasive carcinoma, 70 of whom met inclusion criteria for the present analysis. Results: The median age at surgery was 68 years. The median tumor size was 3.3 cm, and invasive carcinoma was present at the margin in 16% of the patients. Of the 70 patients, 50% had metastases to the lymph nodes and 64% had Stage II disease. The median survival was 28.0 months, and 2- and 5-year survival rate was 57% and 45%, respectively. Of the 70 patients, 40 had undergone adjuvant CRT. Those receiving CRT were more likely to have lymph node metastases, perineural invasion, and Stage II-III disease. The 2-year survival rate after surgery with vs. without CRT was 55.8% vs. 59.3%, respectively (p = NS). Patients with lymph node metastases or positive surgical margins benefited significantly from CRT (p = .047 and p = .042, respectively). On multivariate analysis, adjuvant CRT was associated with improved survival, with a relative risk of 0.43 (95% confidence interval, 0.19-0.95; p = .044) after adjusting for major confounders. Conclusion: Adjuvant CRT conferred a 57% decrease in the relative risk of mortality after pancreaticoduodenectomy for intraductal papillary mucinous neoplasms with an associated invasive component after adjusting for major confounders. Patients with lymph node metastases or positive margins appeared to particularly benefit from CRT after definitive surgery.

AB - Purpose: Intraductal papillary mucinous neoplasms are mucin-producing cystic neoplasms of the pancreas. One-third are associated with invasive carcinoma. We examined the benefit of adjuvant chemoradiotherapy (CRT) for this cohort. Methods and Materials: Patients who had undergone pancreatic resection at Johns Hopkins Hospital between 1999 and 2004 were reviewed. Of these patients, 83 with a resected pancreatic mass were found to have an intraductal papillary mucinous neoplasm with invasive carcinoma, 70 of whom met inclusion criteria for the present analysis. Results: The median age at surgery was 68 years. The median tumor size was 3.3 cm, and invasive carcinoma was present at the margin in 16% of the patients. Of the 70 patients, 50% had metastases to the lymph nodes and 64% had Stage II disease. The median survival was 28.0 months, and 2- and 5-year survival rate was 57% and 45%, respectively. Of the 70 patients, 40 had undergone adjuvant CRT. Those receiving CRT were more likely to have lymph node metastases, perineural invasion, and Stage II-III disease. The 2-year survival rate after surgery with vs. without CRT was 55.8% vs. 59.3%, respectively (p = NS). Patients with lymph node metastases or positive surgical margins benefited significantly from CRT (p = .047 and p = .042, respectively). On multivariate analysis, adjuvant CRT was associated with improved survival, with a relative risk of 0.43 (95% confidence interval, 0.19-0.95; p = .044) after adjusting for major confounders. Conclusion: Adjuvant CRT conferred a 57% decrease in the relative risk of mortality after pancreaticoduodenectomy for intraductal papillary mucinous neoplasms with an associated invasive component after adjusting for major confounders. Patients with lymph node metastases or positive margins appeared to particularly benefit from CRT after definitive surgery.

KW - adjuvant therapy

KW - intraductal papillary mucinous neoplasm

KW - invasive carcinoma

KW - Pancreatic adenocarcinoma

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=76049088876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76049088876&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2009.02.071

DO - 10.1016/j.ijrobp.2009.02.071

M3 - Article

C2 - 19647950

AN - SCOPUS:76049088876

VL - 76

SP - 839

EP - 844

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -